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Objectives The purpose of this study was to evaluate the antihypertensive efficacy of hydrochlorothiazide (HCTZ) by ambula-
tory blood pressure (BP) monitoring.
Background HCTZ is the most commonly prescribed antihypertensive drug worldwide. More than 97% of all HCTZ prescrip-
tions are for 12.5 to 25 mg per day. The antihypertensive efficacy of HCTZ by ambulatory BP monitoring is less
well defined.
Methods A systematic review was made using Medline, Cochrane, and Embase for all the randomized trials that assessed
24-h BP with HCTZ in comparison with other antihypertensive drugs.
Results Fourteen studies of HCTZ dose 12.5 to 25 mg with 1,234 patients and 5 studies of HCTZ dose 50 mg with 229
patients fulfilled the inclusion criteria. The decrease in 24-h BP with HCTZ dose 12.5 to 25 mg was systolic 6.5
mm Hg (95% confidence interval: 5.3 to 7.7 mm Hg) and diastolic 4.5 mm Hg (95% confidence interval: 3.1 to
6.0 mm Hg) and was inferior compared with the 24-h BP reduction of angiotensin-converting enzyme inhibitors
(mean BP reduction 12.9/7.7 mm Hg; p  0.003), angiotensin-receptor blockers (mean BP reduction 13.3/7.8
mm Hg; p  0.001), beta-blockers (mean BP reduction 11.2/8.5 mm Hg; p  0.00001), and calcium antago-
nists (mean BP reduction 11.0/8.1 mm Hg; p  0.05). There was no significant difference in both systolic (p 
0.30) and diastolic (p  0.15) 24-h BP reduction between HCTZ 12.5 mg (5.7/3.3 mm Hg) and HCTZ 25 mg
(7.6/5.4 mm Hg). However, with HCTZ 50 mg, the reduction in 24-h BP was significantly higher (12.0/5.4 mm
Hg) and was comparable to that of other agents.
Conclusions The antihypertensive efficacy of HCTZ in its daily dose of 12.5 to 25 mg as measured in head-to-head studies by
ambulatory BP measurement is consistently inferior to that of all other drug classes. Because outcome data at
this dose are lacking, HCTZ is an inappropriate first-line drug for the treatment of hypertension. (J Am Coll
Cardiol 2011;57:590–600) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.07.053s
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THydrochlorothiazide (HCTZ) has been available for half a
century and remains the most commonly prescribed antihy-
pertensive drug worldwide. In the U.S. alone, 134.1
million prescriptions of HCTZ were written in the year
2008 (1). For comparison, the second most commonly
prescribed drug was atenolol, with 44 million prescriptions
(1). More than a third of the HCTZ prescriptions (47.5
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maccepted July 5, 2010.million) were written for monotherapy and the remainder in
fixed combination, mostly with blockers of the renin-
angiotensin system. The dose of HCTZ prescribed was
almost exclusively (97%) 12.5 to 25 mg/day, and hyperten-
ion remains, by far, the most common indication. Over the
ast 30 years, this persistent prescription pattern of HCTZ has
een heavily influenced by reports of the Joint National
ommittee for Prevention, Detection, Evaluation, and Treat-
ent of High Blood Pressure, all 7 of which recommended
thiazides” or “thiazide-like drugs” or “thiazide-type diuretics”
s first-line or as preferred therapy for hypertension. In an
ttempt to promote the use of thiazide-type diuretics, the
ational Heart, Lung, and Blood Institute sponsored the
LLHAT/JNC7 (Antihypertensive and Lipid-Lowering
reatment to Prevent Heart Attack Trial/Joint National Com-
ittee Seventh Report) dissemination project, which reached
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February 1, 2011:590–600 Hydrochlorothiazide for Hypertension18,524 physicians in 1,698 venues through 147 physician
educators (2). This effort resulted in a small increase in
thiazide-type diuretics use that almost exclusively consisted of
HCTZ. However, despite the extensive use, little evidence is
available regarding the efficacy and safety of HCTZ for the
treatment of essential hypertension, particularly at the dose of
12.5 to 25 mg. In the following paper, we scrutinize antihy-
pertensive efficacy of HCTZ as assessed by 24-h ambulatory
blood pressure (ABP) monitoring and the evidence for mor-
bidity and mortality reduction available in the extensive liter-
ature on this drug.
Methods
Search strategy. We searched PubMed, Embase, and Co-
chrane Central Register of Clinical Trials (Cochrane Li-
brary, Issue 2, 2009) using the terms “HCTZ,” “hydrochlo-
rothiazide,” “ABP,” “ambulatory blood pressure,” and
“hypertension.” We limited our search to randomized trials
in human subjects and in peer-reviewed journals from 1966
to March 2010. No language restriction was applied. The
reference lists of identified articles and bibliographies of
original articles were also reviewed. Trials in the abstract
form without a manuscript published were excluded for this
analysis.
Selection criteria. To be included in the analysis, a trial
had to fulfill the following criteria: 1) randomized trials
involving patients with hypertension that assessed the anti-
hypertensive efficacy by 24-h ABP monitoring comparing
HCTZ with other antihypertensive drug classes; 2) use of
HCTZ as a monotherapy in the trial; and 3) trial duration
of at least 4 weeks.
Data extraction. Two reviewers (J.R. and C.A.) extracted
the data independently and in duplicate. Data were ex-
tracted using standardized protocol and reporting form.
Disagreements were resolved by arbitration (H.M. or A.B.),
and consensus was reached after discussion. We extracted
characteristics of each trial, duration of intervention and
methods, baseline demographics, and 24-h ABP and office
BP at baseline and after the intervention for our analysis.
Authors of the papers were individually contacted in case
the data were unclear.
Outcomes assessed. The main outcome of the present
analysis was BP (systolic/diastolic) reduction from baseline
to follow-up.
Quality assessment. The criteria used for quality assess-
ment were sequence generation of allocation, allocation
concealment, blinding of participants, personnel, and out-
come assessors, incomplete outcome data, selective outcome
reporting, and other sources of bias (3). We classified
tudies with high or unclear risk for bias for any of the first
components as low quality.
tatistical analysis. The statistical analysis was done in line
ith recommendations from the Cochrane Collaboration
nd the Quality of Reporting of Meta-analyses (QUO-
UM) guidelines (4) using Review Manager (RevMan) nersion 5.0.23 (Copenhagen, Nor-
ic Cochrane Centre, The Co-
hrane Collaboration, 2008).
Heterogeneity was assessed
sing the I2 statistics. The I2
statistic is the proportion of total
variation observed between the
trials attributable to differences
between trials rather than sam-
pling error (chance), and we
considered I2 25% as low and
2 75% as high. The random-
ffects model of DerSimonian and Laird (5) was used to
alculate the effect sizes if I2 25% and/or p  0.05.
nalysis was performed on an intention-to-treat basis. Data
rom changes in baseline BP were combined using the
eighted mean difference method. Publication bias was
stimated visually by funnel plots, and/or using Begg’s test
nd the weighted regression test of Egger (6). For trials that
id not provide complete information about variance for net
hange in BP, the information was obtained from confi-
ence intervals (CIs), p value, or t statistics. Variance was
estimated from pre-test–post-test (parallel group and facto-
rial design) and crossover designs, as suggested by Follmann
et al. (7)
Sensitivity analysis. Sensitivity analysis was performed for
BP reduction in HCTZ dose 12.5 to 25 mg based on the
quality of study, study design, and type of blinding in the
study. We estimated difference between subgroups accord-
ing to the tests of interaction (8).
esults
tudy selection. We identified 2,440 articles, out of which
6 abstracts were retrieved and reviewed for possible inclu-
ion (Fig. 1). Nineteen studies (Table 1) enrolling 1,463
atients (mean age 58 years; 54% men) fulfilled the inclu-
ion criteria and were included in the analysis.
aseline characteristics. Of the 19 studies, 14 studies
9–22) enrolling 1,234 patients evaluated HCTZ dose 12.5
o 25 mg, and 5 studies (23–27) with 229 patients evaluated
CTZ dose 50 mg. Of the 14 studies of HCTZ dose of
2.5 to 25 mg, 4 studies evaluated HCTZ 12.5 mg dose, 1
valuated HCTZ 12.5 to 25 mg dose, and the majority (9
tudies) evaluated HCTZ 25 mg dose. Fifteen studies
28–42) were excluded because they did not meet the
nclusion criteria: 5 had inadequate data, 3 were nonran-
omized studies, 2 had HCTZ combined with other drugs
n case of inadequate response, 2 were duplicate studies, 1
ad HCTZ compared with placebo, and 1 had HCTZ
ompared with exercise.
uality assessment. Of the 14 studies with HCTZ dose
2.5 to 25 mg, 4 studies reported adequate generation of
llocation sequence and adequate allocation concealment,
nd 10 reported adequate masking of participants, person-
Abbreviations
and Acronyms
ABP  ambulatory blood
pressure
ACE  angiotensin-
converting enzyme
ARB  angiotensin-
receptor blocker
BP  blood pressure
HCTZ  hydrochlorothiazideel, and outcome assessors. On the basis of quality assess-
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Hydrochlorothiazide for Hypertension February 1, 2011:590–600ment, 4 were deemed as low bias risk trials and the rest as
high bias risk.
Antihypertensive efficacy. The antihypertensive efficacy of
HCTZ in the dose of 12.5 to 25 mg was assessed from 14
randomized controlled trials. The mean baseline BP in these
studies was 148  7.5/92  5.6 mm Hg. After treatment
with HCTZ for a mean duration of 17 weeks, systolic ABP
decreased by 6.5 mm Hg (95% CI: 5.3 to 7.7 mm Hg) and
diastolic ABP by 4.5 mm Hg (95% CI: 3.1 to 6.0 mm Hg)
(Figs. 2 and 3). Other antihypertensive agents such as angio-
tensin-converting enzyme (ACE) inhibitors, angiotensin-
receptor blockers (ARBs), beta-blockers, and calcium an-
tagonists were significantly more efficacious than HCTZ in
Figure 1 Selection of Studies
HCTZ  hydrochlorothiazide.the dose of 12.5 to 25 mg as shown in Figure 2. cead-to-head comparisons. In head-to-head compari-
ons with other antihypertensive drug classes, HCTZ in the
sual dose of 12.5 to 25 mg lowered systolic ABP less well
han ACE inhibitors by 4.5 mm Hg (p  0.001), ARBs by
.1 mm Hg (p  0.003), beta-blockers by 6.2 mm Hg (p 
.00001), and calcium antagonists by 4.5 mm Hg (p 
.02). HCTZ lowered diastolic ABP less well than ACE
nhibitors by 4.0 mm Hg (p  0.0001), ARBs by 2.9 mm
g (p  0.002), beta-blockers by 6.7 mm Hg (p 
.00001), and calcium antagonists by 4.2 mm Hg (p 
.0001) (Figs. 4 and 5).
ffice versus ambulatory pressure. Both office BP and
BP readings were available in 8 studies with HCTZ in theommonly used dose of 12.5 to 25 mg evaluating 488
Baseline Characteristics of Studies Included in the Meta-AnalysisTable 1 Baseline Characteristics of Studies Included in the Meta-Analysis
First Author (Ref #) Study Design Inclusion Criteria n
Follow-Up
(Weeks)
Age
(yrs)
Men
(%)
HCTZ Dose
(mg)
Comparison Drug
(mg)
Baseline ABP
(mm Hg)
HCTZ dose 12.5 to 25 mg
Damasceno et al. (9) 1999 P, DB, CO, R, PC Black hypertensive patients 12 4 NR NR 25 Nifedipine 30 148/99
Falconnet et al. (10) 2004 P, SB, RC, CO Hypertensive patients of East African descent 61 4 49 56 25 Lisinopril 20 139/92
Galzerano et al. (11) 2004 P, DB, RC Mild to moderate essential hypertension 69 52 54 55 25 Telmisartan 80 154/95
Kraiczi et al. (12) 2000 P, DB, CO, RC Hypertensive patients with obstructive sleep apnea 40 12 57 100 25 Amlodipine 5, atenolol 50, enalapril 20, losartan 50 145/92
Lacourcière et al. (14) 1995 P, DB, R, PC Mild to moderate primary hypertension 42 32 69 60 12.5–25 Amlodipine 5–10 154/89
Lacourcière et al. (13) 2003 P, OL, PG, RC Uncomplicated systolic hypertension 120 6 61 55 12.5 Losartan 50 150/86
Pelttari et al. (15) 1998 P, DB, CO, RC Hypertensive patients with obstructive sleep apnea 18 8 52 NR 25 Atenolol 50, isradipine 2.5, spirapril 6 152/105
Suonsyrjä et al. (16) 2008 P, DB, CO, R, PC Finnish men with moderate hypertension 233 4 51 100 25 Amlodipine 5, bisoprolol 5, losartan 50 135/93
Tedesco et al. (17) 1998 P, DB, RC Mild to moderate hypertension 77 95 54 53 25 Losartan 50 156/96
Ubaid-Girioli et al. (18) 2007 P, OL, PG, RC Mild to moderate hypertension 63 12 49 46 25 Irbesartan 150, quinapril 20 136/88
White et al. (19) 2008 P, MC, DB, RC Stage II hypertension 354 8 51 55 25 Ramipril 20 148/92
Wing et al. (20) 2003 P, DB, CO, R, PC Elderly with hypertension 19 6 68 58 12.5 Candesartan 8–16 161/85
Abate et al. (21) 1998 P, MC, DM, DB, RC Mild to moderate hypertension 84 8 78 46 12.5 Pinacidil 25 148/85
Radevski et al. (22) 2002 P, OL, R, PC Black patients with mild to moderate hypertension 42 12 57 33 12.5 Indapamide 2.5 147/94
HCTZ dose 50 mg
Lacourcière et al. (23) 1989 P, DB, PG, RC Mild to moderate hypertension 38 12 57 42 25–50 Zofenopril 30–60 150/94
Morgan et al. (24) 2003 P, DB, CO, R, PC Elderly hypertensive patients 24 8 77 75 50 Atenolol 50, felodipine 10, perindopril 8 157/85
Silagy et al. (25) 1992 P, DB, RC Elderly patients with isolated systolic hypertension 24 6 72 38 25–50 Atenolol 50–100, enalapril 10–20, isradipine 2.5–5 156/76
Weir et al. (26) 1998 P, MC, DB, PG, RC Obese patients with hypertension 124 12 51 62 12.5–50 Lisinopril 10–40 145/89
Wing et al. (27) 1997 P, DB, CO, RC Elderly patients with isolated systolic hypertension 19 4 71 26 25-50 Lacidipine 2–4 160/84
ABP  ambulatory blood pressure; BP  blood pressure; CO  crossover; DB  double blind; DBP  diastolic blood pressure; DM  double masked; FT  forced-titrated; HCTZ  hydrochlorothiazide; HTN  hypertension; MC  multicenter; NR  not reported; OL  open
label; P  prospective; PG  parallel group; R  randomized; RC  randomized controlled; SB  single blind; SBP  systolic blood pressure.
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Hydrochlorothiazide for Hypertension February 1, 2011:590–600patients followed up for a mean of 8 weeks. The mean
baseline office BP was 163  7.5/98  6.5 mm Hg and the
ean ABP was 149  7.4/89  3.6 mm Hg. In these 8
tudies, office BP reduction by HCTZ was systolic 12.4 mm
g (95% CI: 8.1 to 16.6 mm Hg) and diastolic 6.5 mm Hg
95% CI: 3.9 to 9.2 mm Hg). HCTZ lowered mean office
ystolic BP by 4.9 mm Hg (95% CI: 0.8 to 9.0 mm Hg)
etter than by ABP monitoring (p  0.02). Average office
iastolic BP was lowered by 2.5 mm Hg (95% CI: 0.9 to 4.1
m Hg) better than by ABP monitoring (p 0.002) (Fig. 6).
The mean office systolic and diastolic BP reduction with
CTZ 12.5 to 25 mg of 12.4/6.5 mm Hg was not
ignificantly different from the mean office BP reduction
ith ACE inhibitors of 11.8/7.4 mm Hg (p  0.65), with
RBs of 13.3/6.7 mm Hg (p 0.66), with beta-blockers of
2.9/9.9 mm Hg (p  0.71), and with calcium antagonists
f 12.0/9.7 mm Hg (p  0.36).
ose response. The ABP was not significantly different
hen compared between the HCTZ 12.5 dose and the
CTZ 25 mg dose. However, with the HCTZ dose of 50
g, the reduction in systolic ABP was 12.0 (95% CI: 8.2 to
5.9), and the reduction in diastolic ABP was 5.4 (95% CI:
.2 to 7.7). Thus, there was a significant difference in the
ystolic ABP (p  0.04), but not diastolic ABP (p  0.97)
Fig. 7), when compared with the 25 mg dose.
Significant heterogeneity was found to be present in the
BP reduction with HCTZ (Fig. 3), head-to-head com-
arison of HCTZ with ACE inhibitors, ARBs, and calcium
ntagonists (Figs. 4 and 5), comparison of office BP with
BP monitoring of HCTZ (Fig. 6), office BP reduction
ith HCTZ, and BP reduction with different doses of
CTZ (Fig. 7). There was no evidence of publication bias
or any of our analyses. Sensitivity analyses for various
Figure 2 Antihypertensive HCTZ Efficacy
as Assessed by 24-h ABP Monitoring
Compared with hydrochlorothiazide (HCTZ) dose 12.5 to 25 mg, p  0.001 for
other antihypertensive drugs, as assessed by 24-h ambulatory blood pressure
(ABP) monitoring. Bars represent 95% confidence intervals; N indicates number
of studies. ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor
blocker; DBP  diastolic blood pressure (blue bars); SBP  systolic blood
pressure (pink bars).ubgroups based on the study design, blinding, and the risk of bias did not make any noticeable difference to these
utcomes (data not shown).
iscussion
he principal findings of our study are that the most
ommonly prescribed HCTZ dose of 12.5 to 25 mg has
linically significant inferior antihypertensive efficacy com-
ared with other drug classes used to treat hypertension.
ur analysis was based on 24-h ABP monitoring, which is
he most thorough and objective way to assess antihyper-
ensive efficacy. In contrast, the reduction of office BP by
CTZ (12.4/6.5 mm Hg) was similar to the reduction of
ffice BP by ACE inhibitors, ARBs, beta-blockers, and
alcium-channel blockers.
The office BP reduction with ACE inhibitors (11.4/6.4
m Hg) and ARBs (11.6/6.5 mm Hg) obtained from
ochrane meta-analysis (43,44) was similar to that obtained
from our analysis. Thus, when HCTZ is assessed by
outpatient BP measurement, the antihypertensive efficacy
seems comparable to that of other antihypertensive drug
classes. This finding would indicate that HCTZ lowers BP
well during daytime when patients are seen in the physi-
cian’s office but has less effect during the night and early
morning hours. Indeed, Finkielman et al. (28) documented
that the antihypertensive response to HCTZ is overesti-
mated by using office BP measures. In their patient popu-
lation of 228 subjects treated with HCTZ 25 mg daily, the
difference between office BP and 24-h ABP was 4.8/2.1 mm Hg
(p  0.01). This difference is very similar to that found in
our present analysis (4.9/2.5 mm Hg). Thus, assessing the
antihypertensive efficacy of HCTZ by office BP measure-
ments only is deceptive and is prone to provide to physicians
and patients a false sense of security.
Not surprisingly, at a daily dose of 50 mg and above,
HCTZ’s antihypertensive efficacy seems to be similar to
most other drug classes. However, all biochemical adverse
effects such as hypokalemia, hyponatremia, hyperuricemia,
insulin resistance, and visceral fat accumulation are dose
dependent and become clinically more significant with daily
doses exceeding 25 mg (45). Thus, biochemical adverse
ffects of HCTZ may prohibit the prescription of higher
oses in many patients. An additional concern is the risk of
udden cardiac death that has been shown to increase in a
ose dependant fashion with HCTZ doses exceeding 25 mg
aily (46). A recent meta-analysis also showed that the
hlorthalidone reduces systolic BP significantly better than
he HCTZ at equivalent doses of both drugs without
ncrease in the risk of hypokalemia (47).
What then is the evidence that HCTZ reduces morbidity
nd mortality in hypertension? A thorough scrutiny of the
iterature reveals that outcome evidence for low-dose
CTZ is lacking. All outcome studies were done with
igher doses than the currently used 12.5 to 25 mg or with
ther thiazides such as chlorthalidone or indapamide.
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February 1, 2011:590–600 Hydrochlorothiazide for HypertensionHCTZ was compared with and found to be inferior to
enalapril in the large Australian National Blood Pressure 2
study (48), although the exact dose was not specified. In the
MRFIT (Multiple Risk Factor Intervention Trial) study
(49), both HCTZ and chlorthalidone were used, and the
highest mortality rates were found in a subset of hyperten-
sive patients treated with HCTZ, with death most likely
from lethal arrhythmias due to hypokalemia. In 9 clinics
whose staff prescribed HCTZ, the trend of mortality was
unfavorable whereas it was favorable in the 6 clinics whose
staff primarily used chlorthalidone (50). The investigators
Figure 3 Reduction in 24-h ABP With HCTZ 12.5 and 25 mg
Reduction in systolic (top) and diastolic (bottom) 24-h ambulatory blood pressure
Table 1. ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin-receptor
dom; IV  instrumental variables.decided to switch everybody to chlorthalidone, and con-cluded that the more favorable mortality trend was due to “a
change in the diuretic treatment protocol about 5 years after
randomization which involved replacement of HCTZ with
chlorthalidone” (50). On the basis of these data, we have to
conclude that, for the most prescribed antihypertensive drug
in the U.S., outcome evidence is lacking. In its commonly
used dose of 12.5 to 25 mg once a day, there has been no
evidence that HCTZ reduces myocardial infarction, stroke,
or death. This lack of outcome data together with the poor
antihypertensive efficacy should strongly motivate physi-
cians to refrain from prescribing HCTZ as initial therapy in
with hydrochlorothiazide (HCTZ) dose 12.5 to 25 mg. Trial references as in
r; CCB  calcium-channel blocker; CI  confidence interval; df  degrees of free-(ABP)
blockehypertension.
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Hydrochlorothiazide for Hypertension February 1, 2011:590–600The fact that our data indicate that HCTZ in its
commonly used dose is a suboptimal antihypertensive drug
should not prevent it from it being useful in combination
Figure 4 Systolic 24-h ABP Reduction by HCTZ at 12.5 to 25 m
Head-to-head comparison of systolic 24-h ambulatory blood pressure (ABP) reduct
dose of 12.5 to 25 mg with other classes of antihypertensive drugs. Trial referwith a blocker of the renin-angiotensin system such as anACE inhibitor, an ARB, or even a direct renin inhibitor.
Numerous, mostly factorial design studies have shown that
when combined with these drug classes, HCTZ, even at low
ompared With Other Antihypertensive Drugs
h hydrochlorothiazide (HCTZ) at the
as in Table 1; abbreviations as in Figure 3.g C
ion wit
encesdoses, elicits a distinct incremental fall in BP. That would
597JACC Vol. 57, No. 5, 2011 Messerli et al.
February 1, 2011:590–600 Hydrochlorothiazide for Hypertensionindicate that HCTZ is more useful as an “enhancer” or
“sensitizer” for the antihypertensive effect of renin-angiotensin
system blockers than as a monotherapeutic agent. However,
Figure 5 Diastolic 24-h ABP Reduction by HCTZ at 12.5 to 25
Head-to-head comparison of diastolic 24-h ambulatory blood pressure (ABP) reduc
the dose of 12.5 to 25 mg with other classes of antihypertensive drugs. Trialeven when combined with a renin-angiotensin system blocker,outcome data suggest that HCTZ is inferior to amlodipine, as
was reported in the recent ACCOMPLISH (Avoiding Car-
diovascular Events in Combination Therapy in Patients Living
ompared With Other Antihypertensive Drugs
th hydrochlorothiazide (HCTZ) at
ces as in Table 1; abbreviations as in Figure 3.mg C
tion wi
referenWith Systolic Hypertension) study (51).
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Hydrochlorothiazide for Hypertension February 1, 2011:590–600Clinical implications. HCTZ still remains the most com-
monly prescribed antihypertensive drug in the U.S. and
worldwide. The National Heart, Lung and Blood Institute
continues to advocate (2) the use of “thiazide-type diuret-
ics,” which, for practicing physicians, simply means HCTZ
in a daily dose of 12.5 to 25 mg. However, because the
BP-lowering effect of HCTZ is inferior to that of every
other drug class and outcome data at commonly used doses
are nonexistent, its use as a first-line antihypertensive agent
is ill advised. On a milligram-per-milligram basis using
pooled data, chlorthalidone, for which solid outcome data
are available, produced greater reductions in systolic BP
than HCTZ did, while mean changes in potassium were
found to be equivalent (47). Thus, if a clinical indication
calls for a thiazide-type diuretic, chlorthalidone or indap-
amide remain the drugs of choice.
Study limitations. As in other meta-analyses, given the
lack of data in each trial, we did not adjust our analyses for
compliance to assigned therapy. Also, the results are subject
to limitations inherent to any meta-analysis based on
pooling of data from different trials with different designs,
Office BP Reduction
P) reduction with office BP reduction
r abbreviations as in Figure 3.Figure 6 Systolic and Diastolic 24-h ABP Reduction Compared With
Comparison of systolic (top) and diastolic (bottom) 24-h ambulatory blood pressure (AB
with hydrochlorothiazide (HCTZ) dose 12.5 to 25 mg. Trial references as in Table 1; otheFigure 7 Dose Response Curve With Hydrochlorothiazide
Systolic ambulatory blood pressure (ABP) is indicated by yellow bars; diastolic
ABP is indicated by red bars. Compared with HCTZ 25 mg ABP: p  NS versus
12.5 mg (both systolic and diastolic), p  0.0001 versus 50 mg systolic, and
p  NS versus 50 mg diastolic. N indicates number of patients. HCTZ  hydro-
chlorothiazide; NS  not significant.different duration, and different patient groups. The trials
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February 1, 2011:590–600 Hydrochlorothiazide for Hypertensiondid not report cardiovascular outcomes, and hence, the
superiority of ABP monitoring over office BP measurement
for prevention of cardiovascular outcomes cannot be derived
from our study. However, there are solid data establishing
ABP monitoring as a better surrogate end point than office
BP measurement (52). There is also evidence that thiazides
are primarily or only effective for patients with low renin,
salt-volume hypertension, so monotherapy limited to this
group might have shown different results; however, the
design of the meta-analysis precluded examining such a
possibility (53). Although no clear dose range was estab-
ished for other antihypertensive drugs when used for
omparison with HCTZ in this meta-analysis, most of
hese drugs were used in one-half the maximal dose.
onclusions
CTZ in its commonly used dose of 12.5 to 25 mg daily
owers BP significantly less well than do all other drug
lasses as measured in head-to-head studies by ABP mon-
toring. Because of such paltry antihypertensive efficacy and
he lack of outcome data at these doses, physicians should
efrain from prescribing HCTZ as initial antihypertensive
herapy.
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